Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by stanleyon Oct 24, 2011 6:12pm
272 Views
Post# 19177301

RE:New Buyers = Smart Money ? Buy Signal?

RE:New Buyers = Smart Money ? Buy Signal? Terry:[S] Was the purchase by two astute brokers a leading indicator or is the market rewarding BRD for calling a conference call? Was BRD oversold? Brigus Gold to release Q3 financial results Nov. 142011-10-24 13:04 AT - News ReleaseMs. Jennifer Nicholson reportsBRIGUS GOLD'S Q3 EARNINGS RELEASE AND CONFERENCE CALLBrigus Gold Corp. will release its third quarter 2011 earnings results on Monday, Nov. 14, 2011. The company will be hosting a teleconference at 12 p.m. Atlantic Time that day (11 a.m. Toronto/Montreal/New York) to discuss the third quarter 2011 financial results.Analysts and other interested parties wanting to participate in the call should dial 1-877-407-8031 (international 201-689-8031) at least 10 minutes prior to the start of the call. No passcode is required. The teleconference will be recorded. If you are unable to join the teleconference live, you can dial toll-free at 1-877-660-6853 (international 201-612-7415) for a playback; please use account No. 286 and conference ID 381918. The event will be archived and available for replay until midnight on Monday, Nov. 28, 2011. The teleconference will also be webcast live at the company's and available for replay for 90 days.
Bullboard Posts